Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients
NCT ID: NCT01780467
Last Updated: 2013-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
40 participants
INTERVENTIONAL
2013-03-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many decisions involve the possibility of gaining or losing relative to the status quo. The loss aversion behaviour is a cognitive concept explaining that people are more sensitive to the possibility of losing objects or money than they are to the possibility of gaining the same objects or amounts of money.
We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
The second purpose is to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
2 groups :
* 20 parkinsonian patients (tested two times : with and without treatment by L dopa)
* 20 healthy paired control
Description of the protocol for patients :
J0 : Inclusion visit (duration : 4h):
* motor assessment (UPDRS)
* neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin scale, UPPS, MADRS, Hamilton, LARS).
J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or without treatment) :
Each acquisition was composed by an orientation sequence+ an anatomic sequence + a functional sequence.
For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the MRI acquisitions.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Many decisions involve the possibility of gaining or losing relative to the status quo. The loss aversion behaviour is a cognitive concept explaining that people are more sensitive to the possibility of losing objects or money than they are to the possibility of gaining the same objects or amounts of money.
We hypothesised that dopamine could be involved in the loss aversion behaviour. To highlight this, we have chosen a model of dopaminergic depletion : the Parkinson's disease The primary purpose of this protocol is to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
The second purpose is to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
2 groups :
* 20 parkinsonian patients (tested two times : with and without treatment by L dopa)
* 20 healthy paired control
Description of the protocol for patients :
J0 : Inclusion visit (duration : 4h):
* motor assessment (UPDRS)
* neuropsychological and psychiatric assessment (MMS, MATTIS, BREF, Stroop, Ardouin scale, UPPS, MADRS, Hamilton, LARS).
J0+1 day and J0 +2 days : 2 visits of MRI (magnetic resonance imaging) acquisition (with or without treatment) :
Each acquisition was composed by an orientation sequence+ an anatomic sequence + a functional sequence.
For healthy subjects, they have only one visit of 2 hours including a MMS, a MADRS and the MRI acquisitions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients with and without treatment by L dopa)
to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
Role of dopamine
healthy paired control
to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
Role of dopamine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Role of dopamine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men or women aged between 35 -75 years
* Patients with an idiopathic Parkinson's disease according to UKPDSBB criterias with a disease evolution duration : 5-10 years)
* With fluctuations in end of doses + morning akinesia.
* Non dement (MMS\>24 ; Mattis \> 130)
* Affiliated to National Health system
* Having given their informed consent
Healthy controls
* Men or women aged between 35 to 75 years
* Non dement (MMS\>24 )
* Affiliated to National Health system
* Having given their informed consent
Exclusion Criteria
* Patients suffering of an atypical Parkinson syndrome
* Psychiatric pathology
* Tremor form (≥ 3 (item tremor of UPDRS))
* Patients with Impulsive control disorders
* Depression, dementia
* Pregnant
* Under guardianship
* In excluding period for another study
* Any contra-indication to MRI
Healthy subject
* Subject with neurological, psychiatric diseases
* Depression, dementia
* Pregnant
* Under guardianship
* In excluding period for another study
* Any contra-indication to MRI
35 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulla MIGUEL
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Patrick LACARIN
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-002768-28
Identifier Type: -
Identifier Source: secondary_id
CHU-0139
Identifier Type: -
Identifier Source: org_study_id